CD123 CAR-T cells
Sponsors
Hebei Senlang Biotechnology Inc., Ltd., Chongqing Precision Biotech Co., Ltd
Conditions
Acute Myelocytic LeukemiaLeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Phase 1
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
NCT03796390
Start: 2018-12-26End: 2021-06-06Target: 15Updated: 2019-01-11
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04265963
Start: 2019-09-01End: 2024-07-01Target: 45Updated: 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04272125
Start: 2019-12-01End: 2024-07-01Target: 40Updated: 2023-04-18